MacroGenics
MGNX
132 hedge funds and large institutions have $835M invested in MacroGenics in 2016 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 47 increasing their positions, 36 reducing their positions, and 9 closing their positions.
1,075% more call options, than puts
Call options by funds: $2.77M | Put options by funds: $236K
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
31% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 36
10% more capital invested
Capital invested by funds: $760M → $835M (+$75.2M)
6% more funds holding
Funds holding: 125 → 132 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$27.8M |
| 2 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$5.63M |
| 3 |
AG
Artal Group
Luxembourg
|
+$4.46M |
| 4 |
SIM
Spark Investment Management
New York
|
+$3.71M |
| 5 |
Millennium Management
New York
|
+$3.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$22.1M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$13.1M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$5.4M |
| 4 |
O
OrbiMed
New York
|
-$4.03M |
| 5 |
JP Morgan Chase
New York
|
-$3.38M |
MGNX Hedge Fund Activity: Q3 2016 in Review
132 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in MacroGenics (MGNX) for Q3 2016, worth a combined $835M — up 9.9% from $760M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new MGNX positions and 9 closed out — a net gain of 8 holders — while 47 added to existing stakes and 36 trimmed.
The largest buyer was BB Biotech, adding an estimated $27.8M. The largest seller was Point72 Asset Management, cutting an estimated $22.1M.
- 132 institutional investors held MacroGenics (MGNX) as of Q3 2016, up from 125 in Q2 2016.
- Funds reported $835M of MacroGenics stock for Q3 2016, up 9.9% quarter-over-quarter.
- 17 funds opened new MacroGenics positions in Q3 2016 and 9 closed out, a net change of +8 holders.
- The largest MacroGenics buyer in Q3 2016 was BB Biotech, an estimated $27.8M added.
- The largest MacroGenics seller in Q3 2016 was Point72 Asset Management, an estimated $22.1M sold.
Based on aggregated 13F filings for Q3 2016.